Global Myelofibrosis Therapeutics Market 2018-2022
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||773824|
|出版日期||內容資訊||英文 106 Pages
|骨髓纖維化治療藥的全球市場:2018年∼2022年 Global Myelofibrosis Therapeutics Market 2018-2022|
|出版日期: 2018年12月21日||內容資訊: 英文 106 Pages||
骨髓纖維化，是罕見變異的費城染色體陰性骨髓增生性腫瘤(MPN)之一。唯一獲得FDA認證的藥物治療是JAKAVI / JAKAFI(Ruxolitinib)。它是一種有效的口服JAK1 / JAK2抑製劑，用於治療骨髓纖維化患者。HSCT療法有還有配對捐贈者不合適的缺點。也有其他療法，包括輸血和雄激素療法，只能減少骨髓纖維化的貧血副作用。因此，在目前可用的所有治療中，沒有一種是可以完全幫助根除疾病的理想治療方法。Technavio的分析師預測，到2022年，骨髓纖維化治療市場的年複合成長率將超過7％。
Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio's analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.
Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.
The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.
For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.
The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.